A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher.

Unlike treatments that focus on removing plaques that have already formed, levetiracetam works differently. It blocks the production of toxic amyloid beta peptides in the first place.

Scientists show that lecanemab clears amyloid plaques by engaging microglia through its Fc fragment, defining the cellular program behind its therapeutic effect ...

Scientists have created a blood test that can estimate when Alzheimer’s symptoms are likely to begin. By measuring a protein called p-tau217, the model predicts symptom onset within roughly three to ...

An Oregon State University scientist and a team of undergraduate students have uncovered real-time insights into a chemical ...

A team of UC Santa Barbara engineering and molecular biology graduate students has developed software to accelerate the discovery process for therapies ...

Alzheimer’s Research UK renews its flagship Drug Discovery Alliance with significant investment at a pivotal moment for ...

The country is facing a coming wave of dementia for its ageing population, and is investing in research into drugs, ...

In the paper, If You Had One Shot: Scale and Herding in Innovation Experiments, the researchers found that when firms can only run one experiment, this leads to insufficient diversity at the market ...

Fiona Phillips' husband provides heartbreaking update on her Alzheimer’sCredit: ITV ...

An Oregon State University scientist and a team of undergraduate students have uncovered real-time insights into a chemical process linked with Alzheimer's disease, paving the way toward better drug ...

XPro™ is a next-generation, selective soluble TNF inhibitor designed to selectively neutralize soluble TNF (sTNF) and restore ...